Title: Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8 - freem

URL Source: https://freemwiki.com/index.php?mobileaction=toggle_view_mobile&title=Openai%2F6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8

Markdown Content:
_This conversation was exported from ChatGPT_[[1]](https://freemwiki.com/index.php?mobileaction=toggle_view_mobile&title=Openai%2F6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8#cite_note-1)

## gpt-5-1[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=1 "Edit section: gpt-5-1")

### User: What are the odds that Pharmala’s ALA-002 will reach Phase 3 trial?[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=2 "Edit section: User: What are the odds that Pharmala’s ALA-002 will reach Phase 3 trial?")

What are the odds that Pharmala’s ALA-002 will reach Phase 3 trial?

### Assistant: Here’s a clear, realistic estimate based on industry-wide data for Novel Chemical Entities NCEs and what is publicly kn…[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=3 "Edit section: Assistant: Here’s a clear, realistic estimate based on industry-wide data for Novel Chemical Entities NCEs and what is publicly kn…")

Here’s a clear, realistic estimate based on industry-wide data for Novel Chemical Entities (NCEs) and what is publicly known about PharmAla’s ALA-002, a next-generation MDMA analogue.

### ✅ Estimated Odds That ALA-002 Reaches Phase 3[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=4 "Edit section: ✅ Estimated Odds That ALA-002 Reaches Phase 3")

Because ALA-002 is an NCE in psychiatry, the best benchmark is the historical probability that an NCE entering Phase 2 will successfully advance to Phase 3.

##### Industry Probability: Phase 2 → Phase 3[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=5 "Edit section: Industry Probability: Phase 2 → Phase 3")

Across all therapeutic areas:

*   ~30% – 35% For CNS/psychiatry drugs:
*   ~20% – 30%

##### For Novel Psychoactive Compounds (MDMA-like analogues)[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=6 "Edit section: For Novel Psychoactive Compounds (MDMA-like analogues)")

There is very limited historical data, because almost no MDMA analogues have made it through formal pharmaceutical trials. But drugs in psychiatry, especially psychoplastogens, psychedelics, and serotonin-modulating agents, generally fall on the lower end of the progression range due to:

*   high placebo response
*   regulatory uncertainty
*   complex trial design
*   difficulty showing effect size consistency

##### ⭐ Realistic Estimated Probability for ALA-002[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=7 "Edit section: ⭐ Realistic Estimated Probability for ALA-002")

➡️ 20% to 30% chance of reaching Phase 3 (assuming it begins a Phase 2 trial and completes it)

This estimate reflects:

*   It’s an NCE (which historically reduces success rate vs reformulated drugs).
*   It’s in mental health, a category with ~25% Phase 2 → 3 transition rate.
*   ALA-002 is aiming to replicate MDMA-like therapeutic effects, but MDMA-assisted therapy itself has had regulatory headwinds in 2024–2025.

### 🔍 Factors That Could Raise the Odds[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=8 "Edit section: 🔍 Factors That Could Raise the Odds")

*   Strong Phase 1/IB safety profile (appears promising so far).
*   Clear pharmacological advantages vs MDMA (e.g., reduced amphetamine-like effects).
*   Fast-track or breakthrough designation (possible if early data is strong).
*   Small, targeted indication such as treatment-resistant PTSD.

### 🔍 Factors That Could Lower the Odds[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=9 "Edit section: 🔍 Factors That Could Lower the Odds")

*   High cost of Phase 2 trials (PharmAla is a micro-cap company).
*   Regulatory caution after MAPS’s MDMA Phase 3 controversy in 2024.
*   Difficulty showing large effect sizes in short-duration psychiatric trials.
*   Funding risk: A Phase 2 trial requires several million dollars.

### 📌 Bottom Line[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=10 "Edit section: 📌 Bottom Line")

A solid, data-supported estimate is 20–30% probability that ALA-002 will successfully complete Phase 2 and advance to Phase 3.

If you want, I can also break down:

*   The cost probability model
*   Comparison to other next-generation MDMA analogues
*   A risk-adjusted valuation scenario for PharmAla

Just let me know.

## References[edit](https://freemwiki.com/index.php?title=Openai/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8&action=edit&section=11 "Edit section: References")

1.   [↑](https://freemwiki.com/index.php?mobileaction=toggle_view_mobile&title=Openai%2F6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8#cite_ref-1 "Jump up")["ALA-002 Phase 3 Odds"](https://chatgpt.com/share/6931b6bf-ceb4-8001-ad1d-faa66f3cf0b8). ChatGPT. Retrieved 2025-12-06.